Literature DB >> 10562494

The complete DNA sequence of myxoma virus.

C Cameron1, S Hota-Mitchell, L Chen, J Barrett, J X Cao, C Macaulay, D Willer, D Evans, G McFadden.   

Abstract

Myxomatosis in European rabbits is a severely debilitating disease characterized by profound systemic cellular immunosuppression and a high rate of mortality. The causative agent, myxoma virus, is a member of the poxvirus family and prototype of the Leporipoxvirus genus. As a major step toward defining the genetic strategies by which the virus circumvents host antiviral responses, the genomic DNA sequence of myxoma virus, strain Lausanne, was determined. A total of 171 open reading frames were assigned to cover the 161.8-kb genome, including two copies each of the 12 genes that map within the 11.5-kb terminal inverted repeats. Database searches revealed a central core of approximately 120 kb that encodes more than 100 genes that exhibit close relationships to the conserved genes of members of other poxvirus genera. Open reading frames with predicted signal sequences, localization motifs, or homology to known proteins with immunomodulatory or host-range functions were examined more extensively for predicted features such as hydrophobic regions, nucleic acid binding domains, ankyrin repeats, serpin signatures, lectin domains. and structural cysteine spacings. As a result, several novel, potentially immunomodulatory proteins have been identified, including a family with multiple ankyrin-repeat domains, an OX-2 like member of the neural cell adhesion molecule family, a third myxoma serpin, a putative chemokine receptor fragment, two natural killer receptor-like species, and a variety of species with domains closely related to diverse host immune regulatory proteins. Coupled with the genomic sequencing of the related leporipoxvirus Shope fibroma virus, this work affirms the existence of a conserved complement of poxvirus-specific core genes and expands the growing repertoire of virus genes that confer the unique capacity of each poxvirus family member to counter the immune responses of the infected host. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10562494     DOI: 10.1006/viro.1999.0001

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  109 in total

1.  CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses.

Authors:  M Saraiva; A Alcami
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Species-level identification of orthopoxviruses with an oligonucleotide microchip.

Authors:  Sergey Lapa; Maxim Mikheev; Sergei Shchelkunov; Vladimir Mikhailovich; Alexander Sobolev; Vladimir Blinov; Igor Babkin; Alexander Guskov; Elena Sokunova; Alexander Zasedatelev; Lev Sandakhchiev; Andrei Mirzabekov
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Extensive gene gain associated with adaptive evolution of poxviruses.

Authors:  Aoife McLysaght; Pierre F Baldi; Brandon S Gaut
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-05       Impact factor: 11.205

5.  Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome.

Authors:  Chris Upton; Stephanie Slack; Arwen L Hunter; Angelika Ehlers; Rachel L Roper
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  Myxoma virus: propagation, purification, quantification, and storage.

Authors:  Sherin E Smallwood; Masmudur M Rahman; Dorothy W Smith; Grant McFadden
Journal:  Curr Protoc Microbiol       Date:  2010-05

7.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

8.  Myxoma and vaccinia viruses bind differentially to human leukocytes.

Authors:  Winnie M Chan; Eric C Bartee; Jan S Moreb; Ken Dower; John H Connor; Grant McFadden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

10.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.